Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Checked against the public recordLast updated Oct 10, 2024 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- NGM Biopharmaceuticals, Inc
- Interventions being studied
- Drug: NGM831; Drug: NGM831 plus pembrolizumab (KEYTRUDA®); Drug: NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy. * Adequate bone marrow, kidney and liver function * Performance status of 0 or 1. * Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement. Exclusion Criteria: * Prior treatment targeting ILT3. * Prior treatment targeting LAIR1.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- NGM Clinical Study SiteGilbert, Arizona
- NGM Clinical Study SiteLos Angeles, California
- NGM Clinical Study SiteSarasota, Florida
- NGM Clinical Study SiteTampa, Florida
- NGM Clinical Study SiteGrand Rapids, Michigan
- NGM Clinical Study SiteNew York, New York
- NGM Clinical Study SiteOklahoma City, Oklahoma
- NGM Clinical Study SiteAustin, Texas
- NGM Clinical Study SiteHouston, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 10, 2024. Always confirm current availability with the study team.